Relmada Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Relmada Therapeutics is seeking shareholder approval to increase authorized shares and equity incentives following a strategic turnaround and $100 million capital raise.
NASDAQ
Relmada Therapeutics, Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 23, 2025, with proposals including the election of a Class I director, ratification of the accounting firm, and an amendment to the equity incentive plan.
NASDAQ
Relmada Therapeutics is shifting its focus to acquiring and advancing new therapeutic candidates after a Phase 3 trial for esmethadone (REL-1017) showed it was unlikely to meet its primary endpoint.
NASDAQ
Relmada Therapeutics has scheduled its 2024 Annual Meeting for May 24, 2024, and is providing proxy materials to stockholders.
NASDAQ
Relmada Therapeutics is asking stockholders to approve an amendment to its 2021 Equity Incentive Plan to increase the number of shares available for issuance by 4.5 million, as the company progresses with its REL-1017 Phase 3 program and a new metabolic disease program.